Increased propensity for calcium phosphate kidney stones with topiramate use

Expert Opinion on Drug Safety

Volumn 6, Issue 5, 2007, Pages 547-557

  Vega, Damaris ^a   Maalouf, Naim M ^a   Sakhaee, Khashayar ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alkaline urine pH; Calcium phosphate stones; Metabolic acidosis; Topiramate

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BICARBONATE; CALCIUM; CALCIUM OXALATE; CALCIUM PHOSPHATE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CITRATE POTASSIUM; CITRIC ACID; PLACEBO; TOPIRAMATE; ZONISAMIDE; DRUG DERIVATIVE; FRUCTOSE;

ACCOMMODATION DISORDER; ADDICTION; ADJUVANT THERAPY; ALKALINITY; CALCIUM STONE; CALCIUM URINE LEVEL; CARBONATE DEHYDRATASE II DEFICIENCY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONCENTRATION LOSS; CRYSTAL STRUCTURE; DIET THERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FATALITY; DRUG MECHANISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; ECHOGRAPHY; ENZYME DEFICIENCY; ENZYME INHIBITION; EPILEPSY; EYE PAIN; FLUID INTAKE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GRAND MAL EPILEPSY; HEMATURIA; HUMAN; INCIDENCE; KIDNEY CALCIFICATION; KIDNEY TUBULE ACIDOSIS; LENNOX GASTAUT SYNDROME; METABOLIC ACIDOSIS; MIGRAINE; MYOCLONUS EPILEPSY; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOMOTOR DISORDER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TASTE; URINARY EXCRETION; URINE PH; UROGENITAL TRACT DISEASE; VISUAL IMPAIRMENT; WEIGHT REDUCTION; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; METABOLISM;

ANIMALS; CALCIUM PHOSPHATES; FRUCTOSE; HUMANS; KIDNEY CALCULI; RISK FACTORS;

EID: 35348972090     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.5.547     Document Type: Review

References (102)

1. SHANK RP, GARDOCKI JF, VAUGHT JL et al.: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia (1994) 35(2):450-460.
2. SHANK RP, GARDOCKI JF, STREETER AJ, MARYANOFF BE: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia (2000) 41 (1):S3-S9.
3. SKRADSKI S, WHITE HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia (2000) 41(1):S45-S47.
4. GIBBS JW III, SOMBATI S, DELORENZO RJ, COULTER DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia (2000) 41 (1):S10-S16.
5. DELORENZO RJ, SOMBATI S, COULTER DA: Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia (2000) 41(1):S40-S44.
6. WHITE HS, BROWN SD, WOODHEAD JH, SKEEN GA, WOLF HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. (1997) 28(3):167-179.
7. ZHANG X, VELUMIAN AA, JONES OT, CARLEN PL: Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia (2000) 41(1):S52-S60.
8. HERRERO AI, DEL OLMO N, GONZALEZ-ESCALADA JR, SOLIS JM: Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology (2002) 42(2):210-220.
9. ZONA C, CIOTTI MT, AVOLI M: Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci. Lett. (1997) 231(3):123-126.
10. ZONAC, RAGOZZINO D, CIOTTI MT et al.: Sodium, calcium and late potassium currents are reduced in cerebellar granule cells cultured in the presence of a protein complex conferring resistance to excitatory amino acids. Eur. J. Neurosci. (1993) 5(11):1479-1484.
11. GRYDER DS, ROGAWSKI MA: Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. (2003) 23(18):7069-7074.
12. POULSEN CF, SIMEONE TA, MAAR TE, SMITH-SWINTOSKY V, WHITE HS, SCHOUSBOE A: Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochem. Res. (2004) 29(1):275-282.
13. WINUM JY, THIRY A, CHEIKH KE et al.: Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails. Bioorg. Med. Chem. Lett. (2007) 17(10):2685-2691.
14. NISHIMORI I, VULLO D, INNOCENTI A, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. (2005) 48(24):7860-7866.
15. NISHIMORI I, MINAKUCHI T, ONISHI S, VULLO D, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. (2007) 50(2):381-388.
16. BRETON S: The cellular physiology of carbonic anhydrases. JOP (2001) 2(4):159-164.
17. SCHWARTZ GJ, OLSON J, KITTELBERGER AM, MATSUMOTO T, WAHEED A, SLY WS: Postnatal development of carbonic anhydrase IV expression in rabbit kidney. Am. J. Physiol. (1999) 276(4 Part 2):F510-F520.
18. BROWN D, KUMPULAINEN T, ROTH J, ORCI L: Immunohistochemical localization of carbonic anhydrase in postnatal and adult rat kidney. Am. J. Physiol. (1983) 245(1):F110-F118.
19. BROWN D, ZHU XL, SLY WS: Localization of membrane-associated carbonic anhydrase type IV in kidney epithelial cells. Proc. Natl. Acad. Sci. USA (1990) 87(19):7457-7461.
20. VITALE RM, PEDONE C, AMODEO P et al.: Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA. Bioorg. Med. Chem. (2007) 15(12):4152-4158.
21. PURKERSON JM, SCHWARTZ GJ: The role of carbonic anhydrases in renal physiology. Kidney Int. (2007) 71(2):103-115.
22. WINUM JY, TEMPERINI C, EL CHEIKH K et al.: Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J. Med. Chem. (2006) 49(24):7024-7031.
23. MARYANOFF BE, MCCOMSEY DF, COSTANZO MJ, HOCHMAN C, SMITH-SWINTOSKY V, SHANK RP: Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J. Med. Chem. (2005) 48(6):1941-1947.
24. MAREN TH, SANYAL G: The activity of sulfonamides and anions against the carbonic anhydrases of animals, plants, and bacteria. Annu. Rev. Pharmacol. Toxicol. (1983) 23:439-459.
25. KOIKE T, KIMURA E, NAKAMURA I, HASHIMOTO Y, SHIRO M: The first anionic sulfonamide-binding zinc(II) complexes with a macrocyclic triamine: chemical verification of the sulfonamide inhibition of carbonic anhydrase. J. Am. Chem. Soc. (1992) 114:7338-7345.
26. SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrases as targets for medicinal chemistry. Bioorg. Med. Chem. (2007) 15(13):4336-4350.
27. WELCH BJ, GRAYBEAL D, MOE OW, MAALOUF NM, SAKHAEE K: Biochemical and stone-risk profiles with topiramate treatment. Am. J. Kidney Dis. (2006) 48(4):555-563.
28. ELTERMAN RD, GLAUSER TA, WYLLIE E, REIFE R, WU SC, PLEDGER G: A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology (1999) 52(7): 1338-1344.
29. BITON V, MONTOURIS GD, RITTER F et al.: A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology (1999) 52(7):1330-1337.
30. BRANDES JL, SAPER JR, DIAMOND M et al.: Topiramate for migraine prevention: a randomized controlled trial. JAMA (2004) 291(8):965-973.
31. D'AMICO D, GRAZZI L, USAI S, MOSCHIANO F, BUSSONE G: Topiramate in migraine prophylaxis. Neurol. Sci. (2005) 26(2):S130-S133.
32. LIPTON RB, STEWART WF, DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 41(7):646-657.
33. CRANER MJ, KLEIN JP, RENGANATHAN M, BLACK JA, WAXMAN SG: Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann. Neurol. (2002) 52(6):786-792.
34. OKUSE K, CHAPLAN SR, MCMAHON SB et al.: Regulation of expression of the sensory neuron-specific sodium channel SNS in inflammatory and neuropathic pain. Mol. Cell Neurosci. (1997) 10(34):196-207.
35. RASKIN P, DONOFRIO PD, ROSENTHAL NR et al.: Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology (2004) 63(5):865-873.
36. STENLOF K, ROSSNER S, VERCRUYSSE F, KUMAR A, FITCHET M, SJOSTROM L: Topiramate in the treatment of obese subjects with drug-naive Type 2 diabetes. Diabetes Obes. Metab. (2007) 9(3):360-368.
37. TOPLAK H, HAMANN A, MOORE R et al.: Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with Type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int. J. Obes. (2007) 31(1):138-146.
38. ROSENSTOCK J, HOLLANDER P, GADDE KM, SUN X, STRAUSS R, LEUNG A: A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese Type 2 diabetic patients. Diabetes Care (2007) 30(6): 1480-1486.
39. HUSUM H, VAN KAMMEN D, TERMEER E, BOLWIG G, MATHE A: Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology (2003) 28(7):1292-1299.
40. RICHARD D, FERLAND J, LALONDE J, SAMSON P, DESHAIES Y: Influence of topiramate in the regulation of energy balance. Nutrition (2000) 16(10):961-966.
41. BAULAC M, ARZIMANOGLOU A, SEMAH F, CAVALCANTI D: Therapeutic options provided by new antiepileptic drugs. Rev. Neurol. (1997) 155(1):21-33.
42. BRAY GA, HOLLANDER P, KLEIN S et al.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. (2003) 11(6):722-733.
43. ASTRUP A, TOUBRO S: Topiramate: a new potential pharmacological treatment for obesity. Obes. Res. (2004) 12:S167-S173.
44. DODGSON SJ, SHANK RP, MARYANOFF BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia (2000) 41(1):S35-S39.
45. KETTER TA, POST RM, THEODORE WH: Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology (1999) 53(5:2):S53-S67.
46. OHLSSON A, CUMMING WA, PAUL A, SLY WS: Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification. Pediatrics (1986) 77(3):371-381.
47. NAGAI R, KOOH SW, BALFE JW, FENTON T, HALPERIN ML: Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification. Pediatr. Nephrol. (1997) 11(5):633-636.
48. VAINSEL M, FONDU P, CADRANEL S, ROCMANS C, GEPTS W: Osteopetrosis associated with proximal and distal tubular acidosis. Acta Paediatr. Scand. (1972) 61(4):429-434.
49. BREGMAN H, BROWN J, ROGERS A, BOURKE E: Osteopetrosis with combined proximal and distal renal tubular acidosis. Am. J. Kidney Dis. (1982) 2(3):357-362.
50. GORDON EE, SHEPS SG: Effect of acetazolamide on citrate excretion and formation of renal calculi. N. Engl. J. Med. (1957)256(26):1215-1219.
51. SHORVON SD: Safety of topiramate: adverse events and relationships to dosing. Epilepsia (1996) 37(2):S18-S22.
52. ABOU-KHALIL B: Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia (2000) 41(1):S72-S76.
53. BOOTSMA HP, COOLEN F, ALDENKAMP AP et al.: Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. (2004) 5(3):380-387.
54. STEPHEN LJ, SILLS GJ, BRODIE MJ: Topiramate in refractory epilepsy: a prospective observational study. Epilepsia (2000) 41(8):977-980.
55. COPPOLA G, CALIENDO G, VEGGIOTTI P et al.: Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Res. (2002) 51(1-2):147-153.
56. COPPOLA G, CAPOVILLA G, MONTAGNINI A et al.: Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. (2002) 49(1):45-48.
57. WERNESS PG, BROWN CM, SMITH LH, FINLAYSON B: EQUIL2: a BASIC computer program for the calculation of urinary saturation. J. Urol. (1985) 134(6):1242-1244.
58. SAKHAEE K, POINDEXTER JR, GRIFFITH CS, PAK CY: Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. J. Urol. (2004) 172(3):958-961.
59. PAK CY, ADAMS-HUET B: Elucidation of factors determining formation of calcium phosphate stones. J. Urol. (2004) 172(6 Part 1):2267-2270.
60. COE FL, EVAN A, WORCESTER E: Kidney stone disease. J. Clin Invest. (2005) 115(10):2598-2608.
61. HAMM LL, HERING-SMITH KS: Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol. Metab. Clin. North Am. (2002) 31(4):885-893.
62. ARUGA S, WEHRLI S, KAISSLING B et al.: Chronic metabolic acidosis increases NaDC-1 mRNA and protein abundance in rat kidney. Kidney Int. (2000) 58(1):206-215.
63. MELNICK JZ, PREISIG PA, MOE OW, SRERE P, ALPERN RJ: Renal cortical mitochondrial aconitase is regulated in hypo- and hypercitraturia Kidney Int. (1998) 54(1):160-165.
64. MELNICK JZ, SRERE PA, ELSHOURBAGY NA, MOE OW, PREISIG PA, ALPERN RJ: Adenosine triphosphate citrate lyase mediates hypocitraturia in rats. J. Clin. Invest. (1996) 98(10):2381-2387.
65. JENKINS AD, DOUSA TP, SMITH LH: Transport of citrate across renal brush border membrane: effects of dietary acid and alkali loading. Am. J. Physiol. (1985) 249(4 Part 2):F590-F595.
66. BRENNAN S, HERING-SMITH K, HAMM LL: Effect of pH on citrate reabsorption in the proximal convoluted tubule. Am. J. Physiol. (1988) 255(2 Part 2):F301-F306.
67. LEMANN J Jr:. Relationship between urinary calcium and net acid excretion as determined by dietary protein and potassium: a review. Nephron (1999) 81(1):18-25.
68. LEMANN J, LITZOW JR, LENNON EJ: Studies of the mechanism by which chronic metabolic acidosis augments urinary calcium excretion in man. J. Clin Invest. (1967) 46(8):1318-1328.
69. SUTTON RA, WONG NL, DIRKS JH: Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int. (1979) 15(5):520-533.
70. YEH BI, SUN TJ, LEE JZ, CHEN HH, HUANG CL: Mechanism and molecular determinant for regulation of rabbit transient receptor potential type 5 (TRPV5) channel by extracellular pH. J. Biol. Chem. (2003) 278(51):51044-51052.
71. YEH BI, KIM YK, JABBAR W, HUANG CL: Conformational changes of pore helix coupled to gating of TRPV5 by protons. EMBO J. (2005) 24(18):3224-3234.
72. 2+ transport proteins. J. Am. Soc. Nephrol. (2006) 17(3):617-626.
73. KAMEL KS, CHEEMA-DHADLI S, SHAFIEE MA, HALPERIN ML: Dogmas and controversies in the handling of nitrogenous wastes: excretion of nitrogenous wastes in human subjects. J. Exp. Biol. (2004) 207(Part 12):1985-1991.
74. TANG R, NANCOLLAS GH, GIOCONDI JL, HOYER JR, ORME CA: Dual roles of brushite crystals in calcium oxalate crystallization provide physicochemical mechanisms underlying renal stone formation. Kidney Int. (2006) 70(1):71-78.
75. EVAN AP, LINGEMAN JE, COE FL et al.: Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. (2003) 111(5):607-616.
76. 14C]calcium oxalate. Clin. Chim. Acta (1989) 182(3):255-270.
77. MEYER JL, SMITH LH: Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Invest. Urol. (1975) 13(1):36-39.
78. NICAR MJ, HILL K, PAK CY: Inhibition by citrate of spontaneous precipitation of calcium oxalate in vitro. J. Bone. Miner. Res. (1987) 2(3):215-220.
79. SIDHU H, GUPTA R, THIND SK, NATH R: Inhibition of calcium oxalate monohydrate (COM) crystal growth by pyrophosphate, citrate and rat urine. Urol Res. (1986) 14(6):299-303.
80. GREISCHAR A, NAKAGAWA Y, COE FL: Influence of urine pH and citrate concentration on the upper limit of metastability for calcium phosphate. J. Urol. (2003) 169(3):867-870.
81. PREMINGER GM, SAKHAEE K, SKURLA C, PAK CY: Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J. Urol. (1985) 134(1):20-23.
82. PREMINGER GM, SAKHAEE K, PAK CY: Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J. Urol. (1988) 139(2):240-242.
83. BATLLE D, GHANEKAR H, JAIN S, MITRA A: Hereditary distal renal tubular acidosis: new understandings. Annu. Rev. Med. (2001) 52:471-484.
84. LEMANN J Jr, ADAMS ND, WILZ DR, BRENES LG: Acid and mineral balances and bone in familial proximal renal tubular acidosis. Kidney Int. (2000) 58(3):1267-1277.
85. GOODMAN AD, LEMANN J Jr, LENNON EJ, RELMAN AS: Production, excretion, and net balance of fixed acid in patients with renal acidosis. J. Clin. Invest. (1965) 44:495-506.
86. COHEN EP, BASTANI B, COHEN MR, KOLNER S, HEMKEN P, GLUCK SL: Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren's syndrome and distal renal tubular acidosis. J. Am. Soc. Nephrol. (1992) 3(2):264-271.
87. DEFRANCO PE, HARAGSIM L, SCHMITZ PG, BASTANI B: Absence of vacuolar H(+)-ATPase pump in the collecting duct of a patient with hypokalemic distal renal tubular acidosis and Sjogren s syndrome. J. Am. Soc. Nephrol. (1995) 6(2):295-301.
88. JOO KW, JEON US, HAN JS et al.: Absence of H(+)-ATPase in the intercalated cells of renal tissues in classic distal renal tubular acidosis. Clin. Nephrol. (1998) 49(4):226-231.
89. ISMAIL EA, ABUL SAAD S, SABRY MA: Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome. Eur. J. Pediatr. (1997) 156(12):957-962.
90. SLY WS, HEWETT-EMMETT D, WHYTE MP, YU YS, TASHIAN RE: Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc. Natl. Acad. Sci. USA (1983) 80(9):2752-2756.
91. SUNDARAM V, RUMBOLO P, GRUBB J, STRISCIUGLIO P, SLY WS: Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation. Am. J. Hum. Genet. (1986) 38(2):125-136.
92. SATO S, ZHU XL, SLY WS: Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients. Proc. Natl. Acad. Sci. USA (1990) 87(16):6073-6076.
93. PARKS JH, WORCESTER EM, COE FL, EVAN AP, LINGEMAN JE: Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. (2004) 66(2):777-785.
94. GOLD LW, MASSRY SG, ARIEFF AI, COBURN JW: Renal bicarbonate wasting during phosphate depletion. A possible cause of altered acid-base homeostasis in hyperparathyroidism. J. Clin. Invest. (1973) 52(10):2556-2561.
95. LEVISOHN PM, HOLLAND KD: Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav. (2007) 10(4):547-552.
96. HIGASHIHARA E, NUTAHARA K, TAKEUCHI T, SHOJI N, ARAIE M, ASO Y: Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: response, to citrate. J. Urol. (1991) 145(5):942-948.
97. BARNETT SM, JACKSON AH, BRADEN GL et al.: Nephrolithiasis and nephrocalcinosis in children taking topiramate for seizures. American Epilepsy Society. Epilepsia (2003) 44(9:90) (Abstract 1.252).
98. ALARCON-MARTINEZ H. CASAS-FERNANDEZ C, ESCUDERO-RODRIGUEZ N et al.: Nephrolithiasis and topiramate. Rev. Neurol. (2006) 42 (2):91-94.
99. GO T: Effect of antiepileptic drug polytherapy on crystalluria. Pediatr. Neurol. (2005) 32(2):113-115.
100. HIAN-TAT O W-LL, WEI-KIN G, POH-SIM L: Low risk of developing renal stones or nephrocalcinosis in pediatric patients on topiramate-6 and 12 months follow-up. American Epilepsy Society. Epilepsia (2002) 43(7:63) (Abstract 1.172).
101. SAKHAEE K, NICAR M, HILL K, PAK CY: Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int. (1983) 24(3):348-352.
102. SAKHAEE K, ALPERN R, POINDEXTER J, PAK CY: Citraturic response to oral citric acid load. J. Urol. (1992) 147(4):975-976.